InvestorsHub Logo
Followers 67
Posts 16221
Boards Moderated 2
Alias Born 02/14/2011

Re: None

Wednesday, 02/13/2013 1:35:22 PM

Wednesday, February 13, 2013 1:35:22 PM

Post# of 110
12:59 PM Medivation (MDVN +1.2%) gains today after presenting data for its monotherapy enzalutamide, showing it's treatment on prostate cancer has positive results. The study showed that the treatment increased serum testosterone by a mean of 114% at week 25 as compared to its baseline, and the median change in PSA was -99.6%